Home » Stocks » TVTX

Travere Therapeutics, Inc. (TVTX)

Stock Price: $30.56 USD -0.26 (-0.84%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $29.10 -1.46 (-4.78%) Mar 1, 7:32 PM
Market Cap 1.56B
Revenue (ttm) 194.03M
Net Income (ttm) -78.07M
Shares Out 50.93M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $30.56
Previous Close $30.82
Change ($) -0.26
Change (%) -0.84%
Day's Open 31.34
Day's Range 29.95 - 31.60
Day's Volume 420,365
52-Week Range 8.98 - 33.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 10 hours ago

Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 12 hours ago

Shares of Travere Therapeutics (NASDAQ:TVTX) fellĀ in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 31.43% over the past year to ($0.4...

GlobeNewsWire - 13 hours ago

Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint

Benzinga - 3 days ago

Travere Therapeutics (NASDAQ:TVTX) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Travere Therapeutics's Q4 earnings.

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferenc...

Zacks Investment Research - 1 week ago

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 week ago

Travere Therapeutics (TVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatme...

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 7,532,500 shar...

GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 20...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to mark...

Business Wire - 3 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study...

Other stocks mentioned: LGND
Benzinga - 3 weeks ago

Travere Therapeutics Inc (NASDAQ: TVTX) share gains after announcing positive interim results from the ongoing Phase 3 DUPLEX study evaluating sparsentan in focal segmental glomerulosclerosis ...

GlobeNewsWire - 3 weeks ago

Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to s...

GlobeNewsWire - 1 month ago

Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021 Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Travere Therapeutics (TVTX) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021

GlobeNewsWire - 3 months ago

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in Novem...

Seeking Alpha - 3 months ago

Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21

Zacks Investment Research - 4 months ago

Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of...

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement eq...

GlobeNewsWire - 4 months ago

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with foc...

GlobeNewsWire - 5 months ago

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

Seeking Alpha - 6 months ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 7 months ago

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021

Zacks Investment Research - 7 months ago

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of...

Zacks Investment Research - 8 months ago

Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Suc...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price ...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, s...

Seeking Alpha - 9 months ago

Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 10 months ago

Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

GlobeNewsWire - 11 months ago

Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORD...

Seeking Alpha - 1 year ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...

Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Other stocks mentioned: ALKS, ATRA, AUTL, INVA, RTRX
Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for November 7th

Other stocks mentioned: OLED, QRVO, RTRX, TRNS

About TVTX

There is no company description available.

Industry
Pharmaceutical Preparation Manufacturing
Stock Exchange
NASDAQ
Ticker Symbol
TVTX
Full Company Profile

Financial Performance

In 2019, TVTX's revenue was $175.34 million, an increase of 6.75% compared to the previous year's $164.25 million. Losses were -$146.43 million, 42.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is 38.40, which is an increase of 25.65% from the latest price.

Price Target
$38.40
(25.65% upside)
Analyst Consensus: Strong Buy